Phase Ib/Ii Trial Of Tisotumab Vedotin (Tv) +/- Bevacizumab (Bev), Pembrolizumab (Pem), Or Carboplatin (Cbp) In Recurrent Or Metastatic Cervical Cancer (Innovatv 205/Engot-Cx8/Gog-3024).

Ignace Vergote,Nicole Concin,Mansoor Raza Mirza,Camilla Mondrup Andreassen,Domenica Lorusso,Christine N. Gennigens,Susana N. Banerjee,Roisin Eilish O'Cearbhaill,Susana Campos, Leonardo Viana Nicacio,Lamar Eaton,David M. O'Malley,Ibrahima Soumaoro,Bradley J. Monk

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 6|浏览5

暂无评分

摘要

TPS6095Background: Patients (pts) with recurrent/metastatic cervical cancer (r/mCC) receive paclitaxel/platinum or paclitaxel/topotecan ± BEV as first-line standard-of-care therapy. Tissue factor (...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要